Q: Tell us about Data4Cure.

 

A: Data4Cure develops and provides its partners with an integrative platform that combines systems biology, machine learning and AI technologies to turn vast amounts of omics, phenotypic and clinical data (both public and proprietary) into a data-driven biomedical knowledge graph. The platform uses this information to build comprehensive maps of diseases to identify new drug targets and biomarkers, find new indications for existing drugs, and match drugs to patient subtypes. We are proud to work with some of the largest and most innovative pharmaceutical companies and leading research institutions who use our platform to gain new insights from their data and build their internal knowledge networks.

Q: What led you to found Data4Cure?

 

A: As a computer scientist and computational biologist, I am always interested in how we can combine and model different types of data together to better understand complex systems and make better decisions. Around 2013, I was working at UC San Diego, developing and publishing on new network and systems approaches which worked well for simple organisms such as yeast but weren’t yet as effective for human disease. I thought we can do better by bringing in a lot more diverse types of data and merging systems biology with some of the new machine learning and semantic learning technologies that were becoming available. That would require a new set of tools and a computational platform that would start to tie all of the pieces together. I thought the work could be more effective done through a company. So instead of looking to start my own academic lab, I left to start Data4Cure helped by our scientific co-founder Dr. Trey Ideker, key scientific advisors Drs. Lee Hood and Napoleone Ferrara, as well as early investors. We were very fortunate to be joined by extraordinary computational biologists and engineers and began working with pharmaceutical companies to apply some of the integrative systems biology machinery toward patient stratification and drug development. It gave us a good view into the problems people are facing both in terms of specific analytical challenges, as well as the bigger problem of growing knowledge from more and more data.

What we were able to develop over the last three to four years is an integrated system that not only applies many advanced analytical methods to the data but provides a technology platform to iteratively update knowledge based on new data and literature. The resulting information is stored in a dynamic data-driven knowledge graph that is unique to each organization. This technology became the basis for the Biomedical Intelligence Cloud — our SaaS offering for pharmaceutical R&D which we launched last year. We are continuously improving it by curating and feeding in new large datasets and building new applications to address a wider range of analytical problems.

Q: What are some of the key unique ideas behind the Biomedical Intelligence Cloud? What contextual knowledge do you bring in?

 

A: The key idea is convergence of evidence and information coming from multiple sources like multidimensional omics data, phenotypic data, molecular networks and pathways, literature, clinical trials, and other structured and non-structured data that may exist both within the organization and outside in the public domain. Typically information coming from each one of these sources is noisy, incomplete, and difficult to interpret. By putting the data together in context we are able to extract the most robust pieces of information and make better sense of it.

The Biomedical Intelligence Cloud uses a proprietary knowledge graph technology called CURIE to continuously aggregate various pieces of evidence, learn how they fit together and apply them toward interesting problems in the pharmaceutical and clinical R&D. We think of it also as convergence of systems biology and ML/AI because the technology leverages recent methods from machine learning and AI but is also heavily informed by the developments in systems biology and incorporates a lot of prior knowledge from the biomedical domain.

Q: What types of problems in pharmaceutical R&D do you help address and how does systems biology and ML help?

 

A: The platform has applications throughout the drug development pipeline from early target discovery and validation, to mechanism of action and efficacy studies, to patient selection and developing companion diagnostics. In each of these areas there is an opportunity for integrative systems-based modeling but there are also unique challenges. The platform helps address these individual areas using a set of dedicated applications.

For instance, to support target discovery and validation, users might start by building integrative molecular maps of diseases which integrate omics, phenotypic and literature information with molecular networks and pathways to identify the key system components with potential for therapeutic intervention. Precision medicine is all about precisely mapping disease subtypes and predicting how they might respond to therapy either as single agent or as combinations. This is where some of the other applications become useful. We have an application that performs a deep molecular subtyping of disease based on multidimensional omics data and specific disease pathways perturbed in each patient. Other applications couple machine learning algorithms with knowledge of molecular networks and pathways to predict sensitivity or resistance to drugs in specific patient subsets. We currently have over 10 applications available on the platform and are expanding with new ones in the next months.

Q: You will be speaking in the Immunotherapy Track as well as the AI showcase at PMWC 2018. What are the applications of the platform toward immune oncology? Can you give some use case examples of cancer biomarkers that the Biomedical Intelligence Cloud helped discover?

 

A: Immuno-oncology research and clinical trials is one the areas in which our platform has seen the most growth in 2017. We are particularly interested in understanding and predicting which patients across different histologies will respond to specific types of immunotherapy (e.g. PD1 or PD-L1 inhibitors) and which other patients may respond to combination therapies in which IO drugs might be combined with other therapies.

The power of the platform is that we can effectively combine multiple types of data, such as are often generated by the new IO clinical trials and apply a range of systems and ML approaches to make sense of these data. What is emerging is a view of the tumor-immune system interactions in which multiple factors such as cancer subtypes, immune infiltration, neoantigen load, checkpoint expression and tumor clonal evolution each may together determine response.

Our system can extract multidimensional information about disease biology coming from the analysis of large research cohorts and use it to boost signal and increase the ability to make accurate predictions for new clinical trial cohorts. In my talk I plan to discuss several case studies using recent trials in lung adenocarcinoma and melanoma.

We are very excited to contribute to the PMWC 2018 program. We’ve been part of the conference since the very beginning of Data4Cure. Every year the quality of the program and level of participants makes it a phenomenal event for anyone working in the field. The 2018 edition will be particularly interesting for anyone interested in immuno-oncology, and applications of machine learning and AI in medicine.

Data Privacy, the Security, And Ownership

The recent Facebook data breach, genetic data sleuthing by the FBI that led to the Golden State Killer, and the soon-to-be-implemented European General Data Protection Regulation (GDPR), has put data privacy and security front and center.

Read More

Q&A with Jason Crites from IBM & Piers Nash from Health2047 Speaking at PMWC 2018 Michigan in June

Q: What need is IBM and Health2047 addressing in the healthcare/life sciences sector?

Jason (IBM): The industry is undergoing a significant transformation as reimbursement shifts from fee-for-service to value-based outcomes in the face of regulatory uncertainty.

Read More

Dr. Francis Collins of NIH at June PMWC Michigan- Launch of Nationwide Participation Enrollment!

This past Sunday—May 6, 2018—the program reached a major milestone with the start of the nationwide participation enrollment! The All of Us Research Program, part of the Precision Medicine Initiative that was famously announced by President Barack Obama at the 2015 State of the Union address, aims to enroll a total of 1 million Americans.

Read More

Meet Dr. Gil Omenn, Director of the University of Michigan Center for Computational Medicine & Bioinformatics on June 6th at PMWC 2018 Michigan

Q: What are the objectives of the Human Proteome Project and what are some of the recent breakthrough discoveries?

The HUPO Human Proteome Project has two overarching goals: (1) to complete the protein parts list, with at least one protein product from each of the ~20,000 protein-coding genes along with sequence variants, splice variants, and post-translational modifications, with characterization of their functions;…

Read More

Meet Amir Dan Rubin, CEO of One Medical on June 6th at PMWC 2018 Michigan

Q: What are some of the biggest contributors to these challenges and how can we overcome them?

A: One of the underlying challenges driving the rising the cost of health care is that most of the health system’s stakeholders have few incentives, if not outright disincentives, to manage expenditures.

Read More

Interview with Steve Nelson, CEO, UnitedHealthcare Presenting at PMWC 2018 Michigan in June

Q: What’s the biggest misconception about UnitedHealthcare?

That we don’t care, that we’re just a health insurance company that pays or denies medical claims. In reality, helping people is at the core of what we do every day.

Read More

Emerging Technologies are Disrupting Healthcare | PMWC Michigan June 6-7

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Dan Rhodes from Strata Oncology

Q: What need is Strata Oncology addressing?

Despite substantial advances in precision oncology, the majority of advanced cancer patients still do not benefit from comprehensive tumor molecular profiling or precision therapy trials.

Read More

Interview with Lisa McLaughlin from Workit Health

Q: What need is Workit Health addressing?

Drug overdoses killed more Americans last year than were lost during the entire Vietnam War (69,000).

Read More

Interview with Olivier Elemento from Weill Cornell Medicine

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

I direct the Englander Institute for Precision Medicine, an Institute that focuses on using genomics and informatics to make medicine more individualized.

Read More

Interview with Dr. Dunnenberger from NorthShore University HealthSystem

Q: What patient population is NorthShore University HealthSystem serving and which services are you specializing in?

NorthShore is a four hospital community health system with over 100 outpatient medical offices.

Read More

How Artificial Intelligence (AI) Will Potentiate Individualized Medicine

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Jennifer Kloke from Ayasdi

Q: What need is Ayasdi addressing?

Ayasdi is pioneering the application of AI to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Q&A with Eric Topol, Executive Vice President, Scripps Research Institute

Dr. Eric Topol, voted by Modern Healthcare as the most influential physician executive in the United States, shared his thoughts on why people should own and control their own data.

Read More

CMS to Approve Coverage of NGS-based Cancer Testing | Big Pharma’s Response & The effect on PM

Why this is a Big Deal? As we know, private insurers follow suit once Medicare makes a decision such as this. This portends well for genetic testing to become routine standard of care for patients with advanced cancers.

Read More
University of Michigan

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Insights in the Clinic”.

Agenda highlights:

  • Two Track Program will showcase sessions on the latest advancements in precision medicine which include, but are not limited to: Transforming Big Data Into Actionable Information, Personalized Modeling of P4 Health, Emerging Technologies in Precision Medicine, The Economic and Socio-political Aspects of Precision Medicine, Precision Cancer Therapy, Session Scalable Infrastructure/Platforms to Power NGS for the Clinic, Genomic Data and Precision Health, Challenges and Barriers at the Community Setting, Opioid Precision Health, Pharmacogenomics Today and Tomorrow.
  • A lineup of 100+ highly regarded speakers featuring pioneering researchers and authorities across the healthcare and biotechnology sectors – browse select PMWC 2018 SV recorded talks
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
  • Track 2-PMWC 2018 Michigan Showcase, enable 15-minute company presentations on latest novel technologies.  See past PMWC Showcase presenters. Nominate here or apply to present here.

Confirmed thought leaders include:

Lee Hood

Lee Hood

Chief Science Officer, Providence Health

Eric Topol

Eric Topol

Chief Academic Officer, Scripps Health

Francis Collins

Francis Collins

Director of the National Institutes of Health (NIH)

Vicki L. Ellingrod

Vicki L. Ellingrod

Ass. Dir., Michigan Inst. for Clinical & Health Research

Goncalo Abecasis

Nancy Cox

Director, Vanderbilt Genetics Institute

Goncalo Abecasis

Pita Navarro

Head of Clinical Operations and Research, Athelas

Goncalo Abecasis

Goncalo Abecasis

Chair, Department of Biostatistics, UM

Jeffrey Leiden

Jeffrey Leiden

Chairman, President and CEO, Vertex

David Ginsburg

David Ginsburg

Prof., Human Genetics; Investigator, UM

Steve Nelson

Steve Nelson

Chief Executive Officer, UnitedHealthcare

Gil Omenn

Gil Omenn

Dir., Comput. Med. & Bioinformatics Center, UM

Eric Lefkofsky

Eric Lefkofsky

Founder and CEO, Tempus

Steven Leeder

Steven Leeder

Dir., Clin. Pharmacology Children’s Mercy Hospital,(CMH)

Ariella Shikanov

Ariella Shikanov

Assistant Professor, Biomedical Engineering, UM

Lawrence Corey

Lawrence Corey

Presi. & Dir. Emeritus, Fred Hutch Cancer Research Cent.

Amir Dan Rubin

Amir Dan Rubin

President and CEO, One Medical

Isaac (Zac) Kohane

Isaac (Zac) Kohane

Professor of Pediatrics, Harvard University

Sachin Kheterpal

Sachin Kheterpal

Associate Professor, Anesthesiology, UM

Matthias Kretzler

Matthias Kretzler

Professor, Nephrology & Internal Medicine, UM

Arul Chinnaiyan

Arul Chinnaiyan

Professor of Pathology, Medical Institute, UM

Registration: PMWC Conferences

Michigan June 6-7, 2018

First PMWC In Midwest
2 Track Speaker Lineup
Access to the exhibition
Breakfast & lunch refreshments
Award Reception

Having Trouble Registering? We accept all major credit cards. Select 'PayPal Check out' and press 'Pay with Debit or Credit Card'.
Click here or call (650)-961-8877 to contact the PMWC Team for Help or to ask about the academic rate.

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!